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SDiscussion
Dr James D. Luketich (Pittsburgh, Pa). Dr Crabtree, I would
like to congratulate you and your colleagues for a very timely
look at the significant increase we are seeing in referral patients
for stereotactic radiation therapy for stage I non–small cell lung
cancer. My first question relates to the absolute proportion of stage
I patients during this time frame that were referred to stereotactic
radiosurgery of approximately 25%. Given the study is now 3 to 4
years old, are you seeing an increase in that number of 25% that are
actually getting stereotactic radiosurgery, and along those lines, is
the technology changing? CyberKnife, Trilogy, TrueBeam, is
there a single device they are using? Have you seen any advantages
or any comments of one technology over the other?
Regarding the absolute results, you pointed out several things in
the comparison between these groups, and the total comparison
and propensity match showed a significant advantage in the
surgical group at 3 and 5 years in terms of disease-free survival.
Yet in the more detailed analysis, there is a lack of a clinically
significant difference in the regional recurrence, survival or
distant, and in the propensity-matched groups only a modest
improvement in local recurrence. So it seems that SBRT is
working fairly good locally. So if patients are not having local or
regional recurrence at a higher rate, ultimately can you comment
more on the cancer-specific survival? I see that difference in
disease-free survival, and how are you determining at the time of
death in this retrospective review that it was indeed cancer-related
or were you able to do that?
Dr Crabtree. Thank you, Dr Luketich. Great points. The first
point, I don’t have the specific numbers or the percentages of
patients that we have sent to stereotactic radiotherapy over the
time of the study. I would say, generally speaking, over that time
our number of evaluations of clinical stage I lung cancers has
gone up, and perhaps the percentage of stereotactic patients has
gone up slightly as a result of us making an assessment that it
may be adequate in those patients.
I think what we have seen as we have delved into this newer
technology of stereotactic therapy is we have had patients come
out of the woodwork who probably historically would never have
been treated at all or never been evaluated for treatment. Now that
referring physicians are aware of this technology, I think we are
seeing more of those, and that probably accounts for most of the
higher percentage of stereotactic patients that we have seen in this
study.
The second question I think is a very important point, and I
highlighted it in the first point of the conclusions. It is very difficultThe Journal of Thoracic and Carfor us to match these patients, because they’re very disparate
populations. Most of the survival difference that we see in terms
of disease-free survival and overall survival is likely attributed to
some other comorbidities. I will say, however, that the radiation
oncologists make the argument that, because in this population
we see no difference in regional failure or distant failure, that is
an advantage or an argument for stereotactic radiotherapy. We
are still seeing a difference in local recurrence, which I think is
extremely important, and compared with lobectomy, there is about
a 5-fold increase in local recurrence in the stereotactic group.
One more comment on that. The theory that the radiation
oncologists have is that there is some kind of immune effect,
that treating a tumor focally with stereotactic therapy somehow
affects the nodal disease. My potential common sense theory is
that at 3 years, 53% of the stereotactic patients are dead and at 5
years 75% are dead, and we clearly are not very good at defining
recurrences radiographically in the nonliving patient.
Dr Scott Swanson (Boston, Mass). I really enjoyed your talk,
Traves. Along those same lines, I have a couple of questions.
One, 15% nodal disease was seen in your surgical cohort, so
presumably that is true on the radiation side, but yet you couldn’t
demonstrate a local regional failure. So what is your impression or
hypothesis about what happens to those patients?
And number 2, it seems important to really understandmorbidity.
Doyou have any data onmorbidity for the radiation patients? It can’t
be zero, so it is always a little later that you see these radiation side
effects. Are you following these patients and getting a sense for
pneumonias, pulmonary fibrosis, issues around respiration, because
I think with minimally invasive techniques, our morbidity is pretty
limited, and I don’t really understand what it is for SBRT.
Dr Crabtree. Thank you, Dr Swanson. Again, great points.
Again, although there is certainly a higher local recurrence rate
for stereotactic therapy compared with surgery, in terms of
regional and distant recurrences, when we are treating these very
sick patients with multiple comorbidities with stereotactic therapy,
I think that their mortality prevents us from being able to identify
regional and distant recurrences, and I think trying to extrapolate
that data and say that there is some equivalence in a low-risk
population is inappropriate. But we would only be able to answer
that question as more low-risk patients who are surviving are
treated with stereotactic therapy.
The second question is a very important point, because we
certainly take a lot of heat in terms of 30- and 90-day morbidity
in the resected patients. In contrast, most of the stereotactic
complications occur 6 months to even a year out, including
radiation pneumonitis, rib fractures, and pain, and it’s actually
very hard to track those complications in the stereotactic patients.
For purposes of this study, however, I do not have accurate data
on the morbidity of stereotactic therapy.
Dr Nasser Altorki (New York, NY). One of the hardest things is
to document local recurrence after SBRT. Many times I find that if
you operate on these patients for failure, you will find that they
have a small number of interspersed cancer cells within a dense
desmoplastic stroma. How was that done in your study and do
you have any insights into how we do it, documentation of local
recurrence in the SBRT arm?
Dr Crabtree. In this population it was almost all radiographic,
and, as you know, in the stereotactic patients, there is controversydiovascular Surgery c Volume 147, Number 4 1191
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Sin determining based on CT and PET whether or not something
represents a recurrence. This was actually very challenging to
work through with our radiation oncologists, but I reviewed every
one of the cases with the radiation oncologist and determined
radiographically if it was a recurrence.
It should be, in a low-risk population, that we get tissue
confirmation. In this population, that just wasn’t practical.
Dr Arjun Pennathur (Pittsburgh, Pa). With the concern of
limiting toxicity of stereotactic radiosurgery in central lesions
and adjustment of dose taking into account the location of the
tumor, could you tell us howmany of them were peripheral lesions
and how many of them were central lesions, because that in itself
has an implication in terms of toxicity as well as the outcome for
the patients.
The second thing is the issue of tissue diagnosis. Fifteen percent
of the SBRT patients did not have a tissue diagnosis, and in your
propensity matching, you matched for T stage and other factors,
but could you have considered eliminating the patients who did
not have a tissue diagnosis at all from the propensity matching
to get that out of the equation, because some of these patients in
whom you did not have a tissue diagnosis could have had benign
disease or they could have had something like carcinoid or small
cell cancer or something else.
Dr Crabtree. Excellent point. The first question about
whether they were central or peripheral, most of these lesions
were peripheral lesions, partly because obviously the radiation
oncologists know there is more toxicity with the central
lesions, and so most central lesions are currently being done on
study.
For the second question, I think that is very important for us to
also understand in the literature. In our SBRT group for this study,
14% didn’t have a tissue diagnosis. I did include them because it is
kind of the practical nature of the practice. We did a subgroup1192 The Journal of Thoracic and Cardiovascular Suranalysis comparing survival and recurrence of the patients who
had a tissue diagnosis and those who didn’t, and there was no
difference. That is a somewhat crude way to deal with this issue.
That number of 14% is actually much lower than what it was in
our original publication a few years ago.
I would highlight that the Dutch group, who publishes quite a
bit on stereotactic radiotherapy, purports an algorithm based on
PET that can completely clinically predict whether or not someone
has a cancer, and in their most recent publication, only one-third of
the patients actually had a tissue diagnosis, and I think that would
be unacceptable, in a low-risk operable population. There is
nothing better to improve your cancer-specific survival than
treating granulomas with stereotactic therapy.
Dr David C. Rice (Houston, Tex). Traves, a great paper. I really
hate to advocate on behalf of the radiation oncologists here, but, as
you point out, the comorbidity score probably doesn’t take into
account resectability, and, therefore, did you go back and look at
the patients who were treated with radiation to see what their
pulmonary function was, how many of those could not possibly
have a lobectomy anyhow? It seems to me that the comparison
is a little slanted in favor of the lobectomy group here.
Dr Crabtree. That is another great question. Certainly the ACE
comorbidity score that we used was a somewhat crude measure.
The problem is identifying this high-risk population or even
the inoperable population. Even within our Society, we don’t
truly know who these high-risk patients are. Efforts with the
Thoracoscore and the STS database by Dr Boffa and Dr Wright
and Ben Kozower, and even Dr Ferguson yesterday, really shows
that these risk models are not yet robust enough to allow us to truly
identify these high-risk patients.
We did look at pulmonary function in the surgical group, but
because of other comorbidities as well, the data on pulmonary
function were incomplete in the stereotactic group.gery c April 2014
